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and new treatment concepts for this cancer type were dis-
cussed. Strengths, weaknesses, opportunities and threats of 
aromatase inhibitors, tamoxifen and fulvestrant as current 
therapeutic options were talked about. The SWOG S0226 
trial was presented, showing a longer progression-free sur-
vival with the combination of anastrozole and fulvestrant 
which, however, seemed to be limited to patients without 
prior endorine therapy. The higher dose fulvestrant of 500 mg 
was associated in the FIRST trial with a longer time to pro-
gression in metastatic endocrine responsive breast cancer. 
New targeted therapies affecting the mTOR pathway and 
 recent results of the phase III study BOLERO 2 were pre-
sented, demonstrating a longer progression free survival of 
4 months and even a trend to a better overall survival with 
everolimus. Moreover, the effect of everolimus on bone me-
tastasis was highlighted by the GBG RADAR study data. 
Looking for a way to overcome endocrine resistance, further 
studies on mTOR/PI3K pathway inhibitors are planned, such 
as the BELLE trial programme. A new phase II trial with the 
CDK 4-6 Inhibitor PD 0332991 plus letrozole showing a 
 better progression free survival than letrozole alone was also 
presented. The data for the FGF-R pathway as a therapeutic 
target are promising but still under investigation. Overall, 
combining endocrine and targeted therapeutics is a next step 
on our way to tailored medicine, but there is a need for bio-
markers predicting therapy sensitivity.
Data of new chemotherapeutic options in metastatic breast 
cancer were also presented focusing on the palliative charac-
ter of this treatment option. Using nanotechnology, albumin-
bound taxane (nab-paclitaxel) seems to be a good alternative 
to conventional taxanes. The EMBRACE study showed 
2 months longer overall survival for eribulin compared to 
treatment of physician’s choice. The new agent NKTR-102 
which showed promising phase II data is now tested in the 
currently open BEACON trial. The new option of staging 
 patients using new techniques such as molecular imaging 
(PET CT) was also discussed.
PrIME Oncology is a global independent medical educa-
tion organisation focussing on specialist training for oncolo-
gists. Meetings are held in Europe and the US updating the 
physicians on the latest guidelines and treatments for malig-
nancies. PrIME Oncology provides physicians with evidence 
based, state of the art educational activities to improve  patient 
outcomes. The meeting ‘Responding to Challenges in meta-
static Breast Cancer’ was held on January 25–27 in Lisbon. It 
was designed as a workshop consisting of 3 plenary sessions 
with updates on the most recent guidelines and 3 breakout 
sessions where discussions were held and presenting skills 
could be practised. The faculty consisted of the chair of 
the meeting, Fatima Cardoso, MD (Champalimaud Cancer 
Centre, Lisbon), Robert Coleman, MD, FRCP, FRCPE 
 (University of Sheffield, US), Angelo Di Leo, MD, PhD 
 (IstitutoToscanoTumori, Prato, Italy), Alessandra Gennari, 
MD, PhD (Galliera Hospital; Genua, Italy), Nadia Harbeck, 
MD, PhD (University of Munich (LMU), Germany) and 
 Frédérique Penault-Llorca, MD, PhD (Centre Jean Perrin, 
Université d’Allvergne Clermont, France). They were joined 
by Jilly Carter, head of Carter Communications and former 
BBC journalist as a non-medical expert. She shared her 
knowledge of presentation skills and interacting with the 
press. The 23 participants came from the UK, Belgium, 
France, Germany, Italy, Portugal and Greece. Except for the 
German participants, who were gynaecologists, all were medi-
cal oncologist with a 5–10-year experience in treatment of 
solid tumours. At the beginning, Fatima Cardoso gave an ex-
cellent overview about the last years’ developments. Even 
though the diagnostics and treatment of patients with metas-
tasized breast cancer, especially when treated according to 
 recent guidelines, has substantially improved, overall survival 
still does not exceed 2–3 years, showing this disease cannot be 
called a chronic disease yet. 
Therefore, the main focus of the meeting was biomarkers 
and translational research in personalized medicine in meta-
static breast cancer. Especially endocrine responsive disease 
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
10
/2
0/
20
14
 2
:3
9:
22
 P
M
Breast Care 2013;8:464–465Workshop Report ‘Responding to Challenges 
in Metastatic Breast Cancer’
465
The important role of the pathologist in the diagnosis of 
breast cancer was highlighted. Several trials showing changes 
in detection of biomarkers in tumour tissue depending on 
transport or fixation time emphasise the need of correct tissue 
handling for a proper diagnosis and addressed the question of 
quality improvement and standardization. Intratumoural 
 heterogeneity and the change of biomarkers during progres-
sion of metastatic breast cancer were reviewed, highlighting 
the need for re-biopsy: ‘The future is now!’
The second part of the meeting touched on the themes of 
presenting medical data and giving interviews. Jilly Carter 
shared valuable information from her BBC journalist experi-
ence. Main points were the right structure for a presentation 
with a strong beginning, a clear middle part and a memorable 
ending. The need for repetition of important points and for 
enough practice was emphasised. A clear and easy structure 
of power point slides was also demonstrated, avoiding ‘death 
by power point’. In giving interviews, the need to illustrate 
and give examples was pointed out as well as the need to keep 
to one’s key messages. A special method for giving short and 
to the point presentations, called ‘The Elevator Presentation’, 
was practised. Participants had to convince the audience of 
their point of view in 30 seconds.
The meeting also featured training in Oxford debate pre-
sented by participants, discussing the role of biomarkers in 
metastatic breast cancer. The supporters discussed the impor-
tance of re-biopsy when metastases are diagnosed. The oppo-
nents mentioned the difficulty in finding reliable markers 
and that treatment should not be delayed while searching 
for markers. Individual performances and suggestions for 
 improvements were discussed afterwards. The importance of 
giving a passionate talk and entertaining the audience was 
 especially pointed out.
Three breakout sessions were held, in which small groups 
of 6–8 participants separately discussed topics with 2 board 
members each. The first group talked about the organisation 
of a breast centre (chairs: Coleman and DiLeo). The impor-
tance of selecting one’s collaborators was highlighted, as well 
as the need to work in a multidisciplinary team to optimise 
the treatment for each individual patient. Furthermore, the 
importance of collaborating with other hospitals, pharmaceu-
tical companies and researchers was pointed out. Differences 
between the structures of breast centres in the countries of 
the different participants were discussed. Some of us had the 
opportunity, to visit Dr. Cardoso’s new Champalimaud Can-
cer Center as an example for combining individual cancer 
care and personalized medicine with high standards of care 
and translational research. In the second breakout session 
(chairs: Harbeck and Penault-Llorca) the change of different 
biomarkers in the course of a breast cancer patient was 
 discussed based on a case. The importance of re-evaluation 
of biomarkers in metastatic breast cancer was highlighted, 
 especially in patients where the tumour was detected before 
2005 and HER2 had not been routinely analysed. Different 
therapeutic options were discussed; also differences between 
therapeutic regimens in different countries. For instance, in 
the UK, trastuzumab is only reimbursed by the insurance 
companies for one line of treatment in metastatic breast 
 cancer. The last breakout session was about presentation 
skills and writing abstracts for scientific meetings (chairs: 
 Cardoso and Gennari). The chairpersons shared personal 
 experience with presentations on big meetings. Based on 
 abstracts and presentations of the participants the ideal struc-
ture of an abstract and a presentation was developed. Partici-
pants also had to give a talk without slides spontaneously and 
their performance was talked through.
This first Rising Stars in Oncology meeting focussing on 
metastatic breast cancer was a full success. During the whole 
meeting, participants had the chance to talk to the board 
members and received valuable tips for presenting scientific 
research at an international meeting and regarding further 
steps for their education and career. Further meetings are 
planned to support this international network of young on-
cologists in Europe. Therefore, on behalf of all participants, 
the authors want to thank all the organisers and chairpersons.
For further information see www.primeoncology.org.
Fig. 1. The chairs  
and participants.
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